Publikationen in Zusammenarbeit mit Forschern von Hospital of the University of Pennsylvania (10)

2024

  1. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

2021

  1. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407

    Journal of Thoracic Oncology

  2. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer

    Future Oncology, Vol. 17, Núm. 10, pp. 1165-1184

2018

  1. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 13, Núm. 2, pp. 165-183

  2. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

    Clinical Lung Cancer, Vol. 19, Núm. 4, pp. 331-339

2016

  1. Clinicopathologic features of advanced squamous NSCLC

    Journal of Thoracic Oncology, Vol. 11, Núm. 9, pp. 1411-1422

  2. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

    Journal of Thoracic Oncology, Vol. 11, Núm. 12, pp. 2066-2081

2011

  1. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

    British Journal of Cancer, Vol. 104, Núm. 1, pp. 68-74

2010

  1. Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition

    Clinical Cancer Research, Vol. 16, Núm. 18, pp. 4654-4665

1999

  1. Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion

    Annals of Oncology, Vol. 10, Núm. 3, pp. 339-344